Progen Commences First Trial of PI-88 Anti-Cancer Drug

November 1999
Worldwide Biotech;Nov99, Vol. 11 Issue 11, p3
Trade Publication
Provides information on the Phase I trial for PI-88, an anti-cancer drug from Progen Industries Ltd.


Related Articles

  • Four-week prophylaxis safe, effective after abdominal, pelvic surgery.  // Hem/Onc Today;8/10/2009, Vol. 10 Issue 15, p23 

    The article presents the results of a clinical drug trial which revealed the effectiveness of using bemiparin after cancer abdominal or pelvic surgery.

  • New cancer drug PAC-1. Investor's Business Daily // Investors Business Daily;3/3/2015, pA02 

    The article offers information on the cancer drug PAC-1 which enters phase one clinical trials on people in 2015.

  • Investigational Drug Helps Men with Advanced PCa.  // Renal & Urology News;Nov2010, Vol. 9 Issue 11, p32 

    The article offers information on the findings of the phase three study regarding the effect of the investigational agent called abiraterone acetate to men with advanced metastatic prostate cancer (PCa) which was presented at the 35th Annual European Society for Medical Oncology Congress wherein...

  • Enrollment begins for nationwide prostate cancer trial.  // Geriatrics;Dec93, Vol. 48 Issue 12, p23 

    Reports on the enrollment of patients for a large-scale, nationwide prevention trial for prostate cancer sponsored by the National Cancer Institute.

  • Vandetanib may be effective option for treatment of advanced hereditary medullary thyroid cancer. Haigh, Christen; Harris, Jason; Lawrence, Leah; Southall, Jennifer // Hem/Onc Today;2/25/2010, Vol. 11 Issue 4, p32 

    The article discusses research on the use of vandetanib for the treatment of advanced hereditary medullary thyroid cancer, by S. A. Wells and colleagues, published in the 2010 issue of the "Journal of Clinical Oncology."

  • ADVANCED LUNG CANCER MAY NOW BE TREATED WITH TRIAL DRUG. Rodman, Morton J.; Hurley, Mary Lou // RN;Aug94, Vol. 57 Issue 8, p75 

    Reports on the Food and Drug Administration's approval of the drug vinorelbine tartrate (Navelbine) for patients with advanced, unresectable, non-small cell lung cancer. Special program which allows use of investigational drugs; Administration of the drug; Side effects.

  • How does a drug get to phase III trials? Reynolds, Tom; Reynolds, T // JNCI: Journal of the National Cancer Institute;10/04/2000, Vol. 92 Issue 19, p1555 

    Reports on the process and decisions on the advancement of a drug to the different phases of oncology trials. Review of application by the National Cancer Institute's Drug Development Group; Strength of the proposal's credentials, novelty, costs and benefit; Cases of toxicity at doses too low...

  • Untitled.  // BioWorld Today;6/2/2009, Vol. 20 Issue 104, p13 

    The article reports on Seattle, Washington-based Oncothyreon Incorporated's ongoing Phase I trial of the phosphoinositide-3 (PI-3) kinase inhibitor PX-866 in advanced cancer. The study showed that the maximally tolerated dose had not been reached among six of 24 patients that had stable disease....

  • European Journal of Surgical Oncology.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article offers information on the publication of trial results for the drug, Restore-2 which is used in Cytori breast reconstruction cell therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics